An innovative and effective method for the treatment of  METASTATIC PROSTATE CANCER

Therapy with the radiopharmaceutical Lutetium 177-PSMA is:
  • an effective treatment for metastatic prostate cancer,
  • used if other methods are ineffective or poorly tolerated by the patient.
The main goals of the therapy are:
  • to reduce the size of the tumour,
  • to slow down the growth of metastases,
  • to relieve the patient of pain and other symptoms of the disease.
Clinical trials confirm:
  • patients feel much better in a relatively short time after the beginning of the treatment,
  • good rates of efficacy and a high percentage of remissions.
lutetium therapy to decrease PSA Levels and tumour size , effective treatment for metastatic prostate cancer

HOW THE THERAPY WORKS?

There is a protein on the surface of prostate cells called prostate-specific membrane antigen (PSMA). In case of prostate cancer, the amount of PSMA is significantly increased. If prostate cancer has spread (metastasized) to other areas of the body, PSMA will also be detected there. The pharmaceutical 177 Lu-PSMA-I&T is binding with the PSMA receptors on cancer cells, according to the “key-lock” principle, thus the delivered radioactive isotope 177 Lu destroys the cancer cells

1. Request the treatment (by phone or in an electronic form) supplemented with your medical information:

      • records of medical history,

      • latest general clinical and biochemical blood test.

2. Based on these documents, doctors will make an assessment of your health condition and make the decision on the suitability of the therapy.

The primary therapy processes

The drug is administered intravenously and treatment on average consists of 3-6 cycles with an interval of 6-8 weeks.

  • The process of the upcoming procedure will be explained to you.
  • A catheter will be inserted into your arm to administer 177 Lu-PSMA intravenously.
  • 30 minutes before administering 177 Lu-PSMA and up to 4 hours after this procedure, you will be offered to place cooling elements onto the salivary gland zone.
  • 177 Lu-PSMA will be administered by slow injection over a prescribed period of time, approximately 20-30 minutes.
  • To verify the accumulation of 177 Lu-PSMA introduced in the target tissues (in the tumor foci) the next day after the treatment procedure, a scintigraphy examination will be conducted.
Targeted radionuclide therapy Lu - 177 PSMA prostate cancer therapy
Follow-up after treatment with 177 Lu-PSMA:
  • Every 2-3 weeks (depending on the initial level), blood tests will be necessary up to 12 weeks after each treatment cycle.
  • Determination of the level of PSA in accordance with the instructions by our doctor.
  • Determination of indicators of the main functions of your kidneys and liver every 6-8 weeks.
  • Physical examination before each treatment cycle.
  • Scintigraphy on the day after each treatment cycle to assess the accumulation of radiopharmaceutical and the effectiveness of therapy.
Continuing treatment with 177Lu-PSMA:
  • The duration of treatment will be determined in every individual specific case, taking into account the cumulative absorbed dose in the salivary glands and kidneys.
  • According to recent research results, continuing treatment with 177Lu-PSMA can be applied up to 7 cycles without exceeding an acceptable level of toxicity.
  • In most cases, intervals of 6 to 8 weeks between treatment cycles are enough to recover the hematopoietic system up to a sufficient level.

SIDE EFFECTS OF THE THERAPY

Most patients, who receive Lutetium 177-PSMA therapy, do not face serious side effects.

Possible complications:

  • Dryness of the mouth and/or eyes (up to 30% of cases).
  • Nausea and vomiting (up to 10% of cases).
  • Suppression of normal blood formation in metastatic bone lesions.

To book a consultation on most suitable treatment plan options, call (+371) 67 229 522

or fill in the details in the contact form.